// App-Quantinova.ai

5000 : Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Eleni Efstathiou

Principal Investigators

  • Mark Anton Titus

  • Angela De Haas-Amatsaleh

  • Frank Perabo

  • De Phung

  • Patricia Troncoso

  • Taoufik Ouatas

  • Christopher Logothetis

  • Sijin Wen

  • Aileen Hoang

Medical Centers

  • Astellas Pharma Global Development, Leiden, Netherlands

  • The University of Texas MD Anderson Cancer Center, Houston, TXWest Virginia University Health Science Center, Morgantown, WVAstellas Global Development, Northbrook, IL

  • Alexandra General Hospital of Athens, Oncology Department, Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece

  • Astellas Pharma Global Development, Leiden, Netherlands

  • Astellas Pharma Global Development, Inc., Northbrook, IL

Locations

  • United States

  • Greece

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Alkaline phosphatase

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Prednisone

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01650194

Sponsors

  • Astellas Pharma

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved